Welcome to our dedicated page for Columbia Financ SEC filings (Ticker: CLBK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Columbia Financial, Inc. filings document material events for the holding company of Columbia Bank, including furnished earnings releases, Regulation FD presentation materials, governance updates and capital-structure disclosures. Recent 8-K filings record operating and financial results, executive appointments, officer-designation matters and board succession disclosures involving the company and its wholly owned bank subsidiary.
The filing record also covers shareholder voting matters, material agreements and corporate-governance items that relate to Columbia Financial’s public-company reporting obligations. These disclosures connect the company’s banking operations with formal records on financial performance, management responsibilities, board composition and securities-related actions.
Columbia Financial, Inc. director Daria Stacy-Walls reported a routine compensation-related equity award. She acquired 235.5072 common stock-equivalent units at $20.70 per share through the Columbia Bank Stock Based Deferral Plan, where phantom stock held in a rabbi trust will later be settled in actual shares.
Following this grant, she indirectly holds 29,083.1882 common stock-equivalent units in the deferral plan, directly owns 11,255 common shares, and indirectly holds 2,952 stock awards under the 2019 Equity Incentive Plan that vest on March 12, 2027.
Columbia Financial, Inc. senior executive John Klimowich reported an update to his holdings that includes a small stock-based award. On June 12, 2026, he acquired 33.0734 shares of Common Stock at $20.70 per share through a stock-based deferral plan, treated as compensation rather than a market purchase.
The award represents phantom stock purchased on a non-discretionary basis by a trustee under the Columbia Bank Stock Based Deferral Plan and will be settled in shares upon distribution. Following this transaction, his indirect deferral-plan balance is 9,179.7669 shares, and he also holds multiple stock option grants with exercise prices between $15.60 and $18.28, expiring between 2029 and 2036.
Columbia Financial, Inc. President & CEO Thomas J. Kemly reported a small compensation-related stock acquisition and updated his holdings. On June 12, 2026, he acquired 89.7434 shares of common stock at $20.70 per share through a stock-based deferral plan, increasing that indirect position to 69,512.9432 shares.
The filing also lists various indirect common stock holdings through stock awards, spouse, retirement and benefit plans, plus a direct common stock position of 249,269 shares. In addition, he holds several option grants on common stock with exercise prices between about $15.60 and $18.28, expiring from 2029 to 2036. No open-market buys or sells were reported.
Columbia Financial, Inc. director Noel R. Holland reported routine equity compensation activity and updated holdings. On June 12, 2026, 8.2329 shares of phantom common stock at $20.70 per share were credited to his account under a stock-based deferral plan, increasing this indirect position to 10,056.9187 stock unit interests.
He also reported indirect holdings of 2,952 shares as stock awards that vest on March 12, 2027, and 46,280 shares held through a SEP-IRA, plus 36,726 shares held directly. In addition, he holds fully vested stock options covering 83,294 shares of common stock at an exercise price of $15.60 per share, expiring on July 23, 2029.
Columbia Financial, Inc. filed an amended quarterly report mainly to replace two certification exhibits that misidentified the principal financial and accounting officer; the underlying first‑quarter 2026 figures are unchanged.
Total assets were $11.0 billion, with loans receivable of $8.26 billion and deposits of $8.37 billion. Net interest income rose to $60.4 million from $50.3 million, while the provision for credit losses decreased to $956,000. Net income increased to $13.1 million, or $0.13 per diluted share, compared with $8.9 million and $0.09 a year earlier.
Credit quality remained manageable, with non‑accrual loans of $41.4 million and an allowance for credit losses on loans of $68.8 million. The company also detailed a planned second‑step conversion to a fully public holding company and a pending merger with Northfield Bancorp, Inc., with consideration tied to an independent valuation range and subject to extensive regulatory and shareholder approvals.
Columbia Financial, Inc. executive John Klimowich, SEVP & Chief Risk Officer, reported an acquisition of 34.0099 shares of Common Stock at $20.13 per share through a stock-based deferral plan. Following this grant, his indirect holdings in that plan total 9,146.6935 common stock unit interests.
The filing also lists additional indirect Common Stock holdings through various stock award, SERP, SIM, ESOP, and 401(k) arrangements, and 63,662 Common Stock shares held directly. Klimowich continues to hold multiple stock option awards on Common Stock with exercise prices between $15.60 and $18.28, expiring between 2029 and 2036.
Columbia Financial, Inc. President & CEO Thomas J. Kemly reported a compensation-related stock acquisition rather than a market trade. On 2026-05-29, he acquired 92.2847 shares of Columbia Financial common stock at $20.13 per share through a stock-based deferral plan, held as phantom stock units. Following this award, his indirect holdings in that deferral plan total 69,423.1998 stock-based units.
The Form 4 also updates various indirect holdings, including shares held through stock award programs, retirement and benefit plans, and by spouse, as well as a direct holding of 249,269 common shares. In addition, Kemly holds several grants of employee stock options with exercise prices between $15.60 and $18.28 per share and expiration dates ranging from 2029 to 2036, providing the right to purchase underlying common shares if exercised.
Columbia Financial, Inc. (CLBK) files a joint proxy statement/prospectus describing a mutual-to-stock Conversion and a proposed merger to acquire Northfield Bancorp. Columbia Bank MHC’s 73.1% stake will be offered in a public offering of up to 192,625,000 shares at $10.00, with a minimum sale of 142,375,000 shares required to close.
Public Columbia Financial shares will be exchanged for 1.8729–2.5340 shares of the new Columbia Financial, Inc.; the current appraised midpoint conversion value is $2.291 billion. If the Merger closes under the stated assumptions, Columbia Financial, Inc. expects to issue approximately 41,800,140 shares to Northfield stockholders, resulting in pro forma ownership near 84.57%/15.43% (Columbia/Northfield) at the midpoint.
Columbia Financial, Inc. director Noel R. Holland reported routine equity compensation activity and updated holdings. The main new transaction was an acquisition of 8.7082 shares of common stock equivalents at $19.57 per share through a stock-based deferral plan. These phantom stock units are held in a rabbi trust and will be settled in shares of stock upon distribution to Holland. Following this grant, his indirect holdings in the stock-based deferral plan increased to 10,048.6858 shares, alongside other indirect retirement-plan holdings and direct common stock. He also continues to hold fully vested stock options with an exercise price of $15.60 per share expiring in 2029.
Columbia Financial, Inc. President & CEO Thomas J. Kemly reported a routine stock-based compensation change with no open‑market trading. On the date shown, an indirect award of 94.9254 shares of Common Stock was credited under a Stock-Based Deferral Plan at a reference price of $19.57 per share, increasing that plan balance to 69,330.9151 shares.
The filing also lists Kemly’s broader position, including 249,269 directly held common shares and multiple stock option grants under the 2019 Equity Incentive Plan, covering several hundred thousand underlying shares at exercise prices between $15.60 and $18.28 per share. These options have expiration dates ranging from 2029 through 2036 and are either fully vested or vest in scheduled annual installments.